Catalyst Dossier · compiled by Celia 🧫

MERCK (MRK)

Pharmaceutical Preparations · market cap $281.2B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-06-29 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Merck & Co. (MRK) is a large-cap multinational pharmaceutical company with $285B market cap, ~75,000 employees, and $65B in 2025 revenue. The company carries a broad pipeline spanning oncology, infectious disease, cardiovascular, and vaccines, with its lead tracked asset Elbasvir in Phase 3 for Hepatitis C. Near-term catalysts are clustered in Q3 2026, including multiple Phase 2/3 data readouts for assets such as Raludotatug Deruxtecan, SC Tulisokibart, and Paclitaxel combinations, alongside an August 2026 earnings report.

The catalyst path

2026-06-29 (est.)Phase 2 · Olaparibimp 7/10
2026-06-30 (est.)Phase 2 · Rescue medicationimp 7/10
2026-07-06 (est.)Phase 2 · Raludotatug Deruxtecan (R-DXd)imp 7/10
2026-07-06 (est.)Phase 3 · Paclitaxelimp 9/10
2026-07-21 (est.)Phase 2 · Palbociclibimp 7/10
2026-07-23 (est.)Phase 2 · pembrolizumabimp 7/10
2026-08-01 (est.)Phase 3 · SC Tulisokibartimp 9/10
2026-08-04Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Lonafarnib	Phase 2	Breast Cancer
MK1903	Phase 2	Dyslipidemia
Elbasvir	Phase 3	Hepatitis C
denufosol tetrasodium Inhalation Solution	Phase 2	Cystic Fibrosis
CXA-101	Phase 2	Complicated Urinary Tract Infection
V260	Phase 3	Rotavirus Gastroenteritis
Vericiguat tablet	Phase 3	Heart Failure
MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks	Phase 2	Hypercholesterolemia
pegylated interferon	Phase 2	Chronic Hepatitis C
Pegylated interferon alfa-2b (SCH 54031)	Phase 3	Hepatitis C, Chronic
MK-8591A	Phase 3	HIV-1 Infection
Multiple low dose cyclophosphamide	Phase 2	Multiple Myeloma
Prevenar 13™	Phase 3	Pneumococcal Infections
Imipenem	Phase 3	Bacterial Pneumonia
RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent	Phase 3	Vomiting
Zanzalintinib	Phase 3	Renal Cell Carcinoma
denufosol tetrasodium (INS37217)	Phase 2	Cystic Fibrosis
OPT-80	Phase 2	Diarrhea
methotrexate	Phase 3	Psoriasis
5-FU	Phase 3	Metastatic Esophageal Squamous Cell Carcinoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.